Medidata Expands Partnership with The Menarini Group, Deploying Medidata’s Study Build AI Technology to Accelerate Global Oncology Pipeline

Core Insights - The partnership between Medidata and The Menarini Group has evolved to incorporate AI technology, specifically Medidata AI Study Build, to enhance the efficiency of clinical trials in oncology [1][2][3] - Stemline Therapeutics, a subsidiary of Menarini, aims to accelerate the initiation of clinical trials for oncology treatments, significantly reducing the time from protocol finalization to trial startup [2][3] Group 1: Partnership Expansion - Medidata and Menarini have expanded their collaboration after 14 years, focusing on integrating AI into clinical workflows to improve oncology research [1][3] - The use of Medidata AI Study Build technology will allow Stemline to leverage a large clinical data set of over 38,000 trials, automating configurations and expediting trial processes [2][3] Group 2: Impact on Oncology Research - The integration of AI is expected to modernize the trial lifecycle, enhancing the speed and quality of data delivery for oncology research [2][6] - Menarini's CEO emphasized the importance of innovation and the role of Medidata AI in streamlining workflows to bring new treatment options to patients more quickly and safely [2][3] Group 3: Company Background - The Menarini Group is a significant player in the pharmaceutical and diagnostics industry, with a turnover of $5 billion and a focus on high unmet medical needs across various therapeutic areas [7] - Stemline Therapeutics specializes in oncology treatments, with products like elacestrant and tagraxofusp-erzs, and is actively conducting multiple clinical studies to expand its treatment offerings [8]